Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARGX
ARGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARGX News
Analysis of IBB ETF Trading Dynamics
Mar 11 2026
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
Mar 09 2026
stocktwits
VYVGART Shows Promise as Targeted Treatment for Ocular Myasthenia Gravis
Mar 06 2026
Newsfilter
argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Mar 06 2026
Yahoo Finance
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
Feb 27 2026
Benzinga
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Feb 26 2026
Benzinga
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
Feb 26 2026
Newsfilter
argenx SE Q4 Earnings Beat Expectations with Strong Revenue Growth
Feb 26 2026
seekingalpha
argenx Reports $4.2 Billion in 2025 Net Sales, Achieving First Year of Profitability
Feb 26 2026
Newsfilter
argenx Reports Positive Results for VYVGART in Ocular Myasthenia Gravis Treatment
Feb 26 2026
Newsfilter
argenx SE to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
argenx COO to Participate in Healthcare Conference
Feb 23 2026
Newsfilter
Argenx SE Rated as One of the Best Growth Stocks for the Next Decade
Feb 04 2026
Yahoo Finance
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Argenx (ARGX) Receives FDA Priority Review for Vyvgart Expansion Application
Jan 13 2026
seekingalpha
Show More News
